ArticleNPJ precision oncology2025
Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a unique case of locally advanced, inflammatory hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in a young woman. A MammaPrint gene signature performed on the core biopsy indicated a very high risk of recurrence (MammaPrint high risk 2, MPH2). BluePrint 80-gene signature was used for the molecular subtyping and identified the tumor as a basal subtype, resembling triple-negative breast cancer (TNBC) despite the strong estrogen receptor (ER) expression on immunohistochemical (IHC) staining. We treated the patient with a TNBC protocol, incorporating carboplatin and immunotherapy into the anthracycline-based chemotherapy backbone in the neoadjuvant setting. The patient achieved a complete response and remains to be disease-free after 2 years, with ongoing follow-up.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.